Target type: biologicalprocess
Any process that activates or increases the frequency, rate or extent of collateral sprouting in the absence of injury. [GOC:dgh, GOC:dph, GOC:jid, GOC:lm]
Positive regulation of collateral sprouting in the absence of injury is a complex process that involves the intrinsic capacity of neurons to respond to environmental cues and modify their growth patterns. This process is distinct from the more well-studied response to injury, where neuronal damage triggers a robust sprouting response. In the absence of injury, this process is driven by subtle changes in the neuronal microenvironment, such as alterations in neurotrophic factor availability or changes in the activity of surrounding neurons. Here are the key steps involved:
1. **Environmental cues:** Neurons constantly monitor their surroundings for signals that indicate a need for growth or rewiring. These cues could include changes in the levels of neurotrophic factors, the activity of neighboring neurons, or even the presence of specific molecules in the extracellular matrix.
2. **Signal transduction:** When these environmental cues are detected, they trigger a cascade of intracellular signaling pathways within the neuron. These pathways involve various molecules, including kinases, phosphatases, and transcription factors.
3. **Gene expression and protein synthesis:** The activated signaling pathways lead to changes in gene expression, resulting in the production of new proteins that are essential for sprouting. These proteins include growth factors, cytoskeletal components, and enzymes involved in axon guidance.
4. **Axonal outgrowth and guidance:** The newly synthesized proteins contribute to the growth and extension of new axons from the existing neuron. These axons follow specific guidance cues, such as gradients of chemoattractants and chemorepellents, to navigate through the tissue and reach their target destinations.
5. **Synapse formation:** Once the new axons reach their target, they form new synapses with other neurons, establishing new connections and facilitating communication between neuronal circuits.
6. **Functional integration:** The newly formed synapses are integrated into the existing neuronal circuitry, contributing to the overall function and plasticity of the neural network.
This process is thought to be important for maintaining neuronal plasticity and adapting to changing environmental conditions, even in the absence of injury. It allows for the fine-tuning of neuronal connections and the establishment of new pathways that enhance communication and optimize brain function.'
"
Protein | Definition | Taxonomy |
---|---|---|
Protein Wnt-3a | A protein Wnt-3a that is encoded in the genome of human. [PRO:DNx, UniProtKB:P56704] | Homo sapiens (human) |
Proto-oncogene Wnt-3 | A proto-oncogene Wnt-3 that is encoded in the genome of human. [PRO:DNx, UniProtKB:P56703] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
iwr-1 exo | IWR-1-exo : A dicarboximide having an exo bridged phthalimide structure, substituted at nitrogen by a 4-(quinolin-8-ylcarbamoyl)benzoyl group. It is a weak axin stabilizer, an analogue of IWR-1-endo. | bridged compound; dicarboximide | axin stabilizer |
WAY-316606 | WAY-316606 : A sulfonamide resulting from the formal condensation of the sulfonic acid group of 5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonic acid with the primary amino group of piperidin-4-amine. An inhibitor of secreted Frizzled-Related Protein-1 (sFRP-1). | (trifluoromethyl)benzenes; piperidines; secondary amino compound; sulfonamide; sulfone | secreted frizzled-related protein 1 inhibitor |
CCT251545 | CCT251545 : A chloropyridine that is 3-chloropyridine substituted by a 1-oxo-2,8-diazaspiro[4.5]decan-8-yl group and a 4-(1-methyl-1H-pyrazol-4-yl)phenyl group at positions 4 and 5, respectively. It is an orally bioavailable inhibitor of Wnt signaling (IC50 = 5 nM) and a potent and selective chemical probe for cyclin-dependent kinases CDK8 and CDK19. CCT251545: a Wnt signaling inhibitor; structure in first source | azaspiro compound; chloropyridine; pyrazoles | antineoplastic agent; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor; Wnt signalling inhibitor |
xav939 | XAV939 : A thiopyranopyrimidine in which a 7,8-dihydro-5H-thiopyrano[4,3-d]pyrimidine skeleton is substituted at C-4 by a hydroxy group and at C-2 by a para-(trifluoromethyl)phenyl group. XAV939: selectively inhibits beta-catenin-mediated transcription; structure in first source | (trifluoromethyl)benzenes; thiopyranopyrimidine | tankyrase inhibitor |
nvp-tnks656 |